BIAF Nasdaq

bioAffinity Technologies, Inc.

BIAF | $2.26 -3.0% 25K

(0.0% 1d) (46.3% 1m) (-71.1% 1y) (0.0% 2d) (0.0% 3d) (-5.9% 7d) (-17.3% volume)
Earnings Calendar:
Market Cap: $ 16,525,052

Sec Filling | Patents | 2022 employees

machine learning respiratory lung cancer

add to watch list email alert is off

Press-releases

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| 50.94% | O: 18.87% H: 0.0% C: 0.0%
research respiratory trial results publication

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments
Published: 2023-01-04 (Crawled : 15:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| Email alert Add to watchlist
award patent for cancer

Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)
Published: 2022-12-19 (Crawled : 17:00) - prnewswire.com
BIAF | $2.26 -3.0% 25K

| 19.4% | O: -1.99% H: 5.58% C: -4.57%
research report

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting
Published: 2022-12-01 (Crawled : 14:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| -11.11% | O: 1.26% H: 2.05% C: 1.32%
research meeting cancer

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-14 (Crawled : 13:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| -7.69% | O: 3.46% H: 0.0% C: 0.0%
financial update results

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
Published: 2022-11-10 (Crawled : 15:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| 0.63% | O: 1.05% H: 14.52% C: 6.22%

bioAffinity Technologies to Report Third Quarter 2022 Financial Results
Published: 2022-11-08 (Crawled : 13:20) - biospace.com/
BIAF | $2.26 -3.0% 25K

| -7.34% | O: 2.14% H: 5.22% C: -0.96%
report financial results

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference
Published: 2022-10-12 (Crawled : 13:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| -11.76% | O: 2.94% H: 2.68% C: -0.36%
lung conference flow results

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M
Published: 2022-09-28 (Crawled : 12:20) - feed.businesswire.com
BIAF | $2.26 -3.0% 25K

| 7.62% | O: 61.43% H: 17.5% C: -18.89%
offering

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE
Published: 2022-09-14 (Crawled : 13:00) - biospace.com/
BIAF | $2.26 -3.0% 25K

| -45.21% | O: 30.14% H: 19.3% C: -14.74%
lung for health flow one results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-22-034472	4	2022-12-05	2022-11-17	Buy	A	3619	3619
0001493152-22-034379	4	2022-12-03	2022-08-31	Buy	P	4081	4081
0001493152-22-034379	4	2022-12-03	2022-08-31	Buy	P	4081	4081
0001493152-22-034379	4	2022-12-03	2022-08-31	Buy	P	4081	4081